<p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 获取免费报告）周五股价下跌了 5.6%。该公司交易最低价为 37.03 美元，最后交易价为 36.31 美元。在交易过程中，约有 6,030 股易手，较平均每日交易量 385,349 股下降了 98%。该股票此前收盘价为 38.45 美元。</p>
<h2>分析师设定新目标价</h2>
<p>多家券商最近对 PRAX 发表了评论。Needham &amp; Company LLC 在 5 月 5 日的报告中重申了对 Praxis Precision Medicines 的 “买入” 评级，并设定了 80.00 美元的目标价。Chardan Capital 在 5 月 7 日的报告中开始覆盖 Praxis Precision Medicines 的股票，给予 “买入” 评级和 80.00 美元的目标价。Wedbush 在 5 月 5 日的报告中将 Praxis Precision Medicines 的目标价从 26.00 美元上调至 28.00 美元，并给予该公司 “跑输大盘” 的评级。Truist Financial 在 3 月 3 日的报告中将 Praxis Precision Medicines 的目标价从 175.00 美元下调至 85.00 美元，并对该股票设定了 “买入” 评级。最后，Robert W. Baird 在 3 月 3 日的研究报告中将 Praxis Precision Medicines 的目标价从 117.00 美元下调至 73.00 美元，并给予该股票 “跑赢大盘” 的评级。一位研究分析师对该股票给予了卖出评级，九位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 的共识评级为 “适度买入”，平均目标价为 116.50 美元。</p>
<p><strong>查看我们对 Praxis Precision Medicines 的最新分析</strong></p>
<h2>Praxis Precision Medicines 股价下跌 2.6%</h2>
<p>该股票的 50 日简单移动平均线为 35.57 美元，200 日简单移动平均线为 57.53 美元。该公司的市值为 7.6272 亿美元，市盈率为-3.61，贝塔值为 2.65。</p>
<p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近一次发布财报是在 5 月 2 日。该公司报告本季度每股收益为（3.29 美元），低于分析师共识预期的（3.20 美元）0.09 美元。Praxis Precision Medicines 的股本回报率为-54.86%，净利润率为-9,409.22%。作为一个整体，股票分析师预计 Praxis Precision Medicines, Inc.在当前年度的每股收益将为-10.22 美元。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近增加或减少了对该股票的持股。GF Fund Management CO. LTD.在第四季度购买了 Praxis Precision Medicines 的新股份，价值 30,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度购买了 Praxis Precision Medicines 的新股份，价值 48,000 美元。GAMMA Investing LLC 在第一季度将其在 Praxis Precision Medicines 的持股增加了 6,075.4%。GAMMA Investing LLC 现在拥有该公司 4,014 股股票，价值 152,000 美元，此前在上个季度购买了额外的 3,949 股。Graham Capital Management L.P.在第四季度购买了 Praxis Precision Medicines 的新股份，价值约 209,000 美元。最后，KLP Kapitalforvaltning AS 在第四季度购买了 Praxis Precision Medicines 的新股份，价值 215,000 美元。目前 67.84% 的股票由机构投资者持有。</p>
<h2>Praxis Precision Medicines 公司简介</h2>
<p>（获取免费报告）</p>
<p>Praxis Precision Medicines, Inc.是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行针对特发性震颤的第三阶段临床试验；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票比 Praxis Precision Medicines 更好</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>英特尔的转机可能是无人关注的最佳投资</li>
<li>10 只最佳航空公司股票推荐</li>
<li>3 只国防股票将从金色圆顶中获利</li>
<li>股息王宝洁在财报后疲软时值得买入</li>
<li>ASML 股票可能是这个价格下最安全的芯片投资</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
<p>在考虑 Praxis Precision Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Praxis Precision Medicines 并不在名单上。</p>
<p>虽然 Praxis Precision Medicines 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

PRAX

<p>Praxis Precision Medicines（纳斯达克代码：PRAX）股价下跌 5.6%，至 36.31 美元，交易量较平均水平下降 98%。分析师们的看法不一，Needham & Company 和 Chardan Capital 维持 “买入” 评级，目标价为 80 美元，而 Wedbush 和 Robert W. Baird 则大幅下调了他们的目标价。该股票的共识评级为 “适度买入”，平均目标价为 116.50 美元。公司报告每股亏损 3.29 美元，未能达到预期，市值为 7.6272 亿美元</p>

<p>Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) shares dropped 5.6% on Friday . The company traded as low as $37.03 and last traded at $36.31. Approximately 6,030 shares changed hands during trading, a decline of 98% from the average daily volume of 385,349 shares. The stock had previously closed at $38.45.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 获取免费报告）周五股价下跌了 5.6%。该公司交易最低价为 37.03 美元，最后交易价为 36.31 美元。在交易过程中，约有 6,030 股易手，较平均每日交易量 385,349 股下降了 98%。该股票此前收盘价为 38.45 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of brokerages recently commented on PRAX. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and set a $80.00 price target on shares of Praxis Precision Medicines in a report on Monday, May 5th. Chardan Capital started coverage on shares of Praxis Precision Medicines in a report on Wednesday, May 7th. They issued a &#34;buy&#34; rating and a $80.00 price objective for the company. Wedbush lifted their target price on Praxis Precision Medicines from $26.00 to $28.00 and gave the company an &#34;underperform&#34; rating in a report on Monday, May 5th. Truist Financial decreased their price target on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, March 3rd. Finally, Robert W. Baird lowered their target price on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an &#34;outperform&#34; rating on the stock in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Praxis Precision Medicines has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $116.50.</p>
<div class="lb-trans"><p>多家券商最近对 PRAX 发表了评论。Needham &amp; Company LLC 在 5 月 5 日的报告中重申了对 Praxis Precision Medicines 的 “买入” 评级，并设定了 80.00 美元的目标价。Chardan Capital 在 5 月 7 日的报告中开始覆盖 Praxis Precision Medicines 的股票，给予 “买入” 评级和 80.00 美元的目标价。Wedbush 在 5 月 5 日的报告中将 Praxis Precision Medicines 的目标价从 26.00 美元上调至 28.00 美元，并给予该公司 “跑输大盘” 的评级。Truist Financial 在 3 月 3 日的报告中将 Praxis Precision Medicines 的目标价从 175.00 美元下调至 85.00 美元，并对该股票设定了 “买入” 评级。最后，Robert W. Baird 在 3 月 3 日的研究报告中将 Praxis Precision Medicines 的目标价从 117.00 美元下调至 73.00 美元，并给予该股票 “跑赢大盘” 的评级。一位研究分析师对该股票给予了卖出评级，九位分析师对该公司给予了买入评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 的共识评级为 “适度买入”，平均目标价为 116.50 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Praxis Precision Medicines</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Praxis Precision Medicines 的最新分析</strong></p>
</div><h2>Praxis Precision Medicines Trading Down 2.6%</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股价下跌 2.6%</h2>
</div><p>The stock has a 50 day simple moving average of $35.57 and a 200 day simple moving average of $57.53. The firm has a market capitalization of $762.72 million, a PE ratio of -3.61 and a beta of 2.65.</p>
<div class="lb-trans"><p>该股票的 50 日简单移动平均线为 35.57 美元，200 日简单移动平均线为 57.53 美元。该公司的市值为 7.6272 亿美元，市盈率为-3.61，贝塔值为 2.65。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its earnings results on Friday, May 2nd. The company reported ($3.29) earnings per share for the quarter, missing analysts' consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%. As a group, equities analysts anticipate that Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current year.</p>
<div class="lb-trans"><p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近一次发布财报是在 5 月 2 日。该公司报告本季度每股收益为（3.29 美元），低于分析师共识预期的（3.20 美元）0.09 美元。Praxis Precision Medicines 的股本回报率为-54.86%，净利润率为-9,409.22%。作为一个整体，股票分析师预计 Praxis Precision Medicines, Inc.在当前年度的每股收益将为-10.22 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new stake in Praxis Precision Medicines in the fourth quarter worth $30,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Praxis Precision Medicines in the 4th quarter worth $48,000. GAMMA Investing LLC raised its position in Praxis Precision Medicines by 6,075.4% in the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock worth $152,000 after buying an additional 3,949 shares during the last quarter. Graham Capital Management L.P. purchased a new position in shares of Praxis Precision Medicines during the fourth quarter valued at approximately $209,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Praxis Precision Medicines during the 4th quarter valued at $215,000. 67.84% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该股票的持股。GF Fund Management CO. LTD.在第四季度购买了 Praxis Precision Medicines 的新股份，价值 30,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度购买了 Praxis Precision Medicines 的新股份，价值 48,000 美元。GAMMA Investing LLC 在第一季度将其在 Praxis Precision Medicines 的持股增加了 6,075.4%。GAMMA Investing LLC 现在拥有该公司 4,014 股股票，价值 152,000 美元，此前在上个季度购买了额外的 3,949 股。Graham Capital Management L.P.在第四季度购买了 Praxis Precision Medicines 的新股份，价值约 209,000 美元。最后，KLP Kapitalforvaltning AS 在第四季度购买了 Praxis Precision Medicines 的新股份，价值 215,000 美元。目前 67.84% 的股票由机构投资者持有。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.是一家临床阶段的生物制药公司，专注于开发针对中枢神经系统疾病的治疗，这些疾病的特征是神经元兴奋 - 抑制失衡。该公司正在开发 ulixacaltamide，这是一种 T 型钙通道的小分子抑制剂，目前正在进行针对特发性震颤的第三阶段临床试验；PRAX-562 用于治疗患有发育性和癫痫性脑病（DEE）的儿童患者；以及 PRAX-628 用于治疗局灶性癫痫。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li>
<li>Intel’s Turnaround May Be the Best Bet No One’s Watching</li>
<li>10 Best Airline Stocks to Buy</li>
<li>3 Defense Stocks That Will Profit From a Golden Dome</li>
<li>Dividend King Proctor &amp; Gamble Is A Buy On Post-Earnings Weakness</li>
<li>ASML Stock Might Be the Safest Chip Play at This Price</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Praxis Precision Medicines 更好</li>
<li>掌握纪律：克服交易中的情绪挑战</li>
<li>英特尔的转机可能是无人关注的最佳投资</li>
<li>10 只最佳航空公司股票推荐</li>
<li>3 只国防股票将从金色圆顶中获利</li>
<li>股息王宝洁在财报后疲软时值得买入</li>
<li>ASML 股票可能是这个价格下最安全的芯片投资</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Praxis Precision Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Praxis Precision Medicines 并不在名单上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Praxis Precision Medicines 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Praxis Precision Medicines (NASDAQ:PRAX) 股价下跌 5.6% - 你是否应该卖出？